JP2022522011A5 - - Google Patents

Info

Publication number
JP2022522011A5
JP2022522011A5 JP2021550227A JP2021550227A JP2022522011A5 JP 2022522011 A5 JP2022522011 A5 JP 2022522011A5 JP 2021550227 A JP2021550227 A JP 2021550227A JP 2021550227 A JP2021550227 A JP 2021550227A JP 2022522011 A5 JP2022522011 A5 JP 2022522011A5
Authority
JP
Japan
Prior art keywords
sequence
pharmaceutical composition
antibody
fragment
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021550227A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022522011A (ja
JP7710374B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/020343 external-priority patent/WO2020176844A1/en
Publication of JP2022522011A publication Critical patent/JP2022522011A/ja
Publication of JP2022522011A5 publication Critical patent/JP2022522011A5/ja
Application granted granted Critical
Publication of JP7710374B2 publication Critical patent/JP7710374B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021550227A 2019-02-28 2020-02-28 骨肉腫を治療するための組成物及び使用方法 Active JP7710374B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962811938P 2019-02-28 2019-02-28
US62/811,938 2019-02-28
PCT/US2020/020343 WO2020176844A1 (en) 2019-02-28 2020-02-28 Compositions for treating osteosarcoma and methods of use

Publications (3)

Publication Number Publication Date
JP2022522011A JP2022522011A (ja) 2022-04-13
JP2022522011A5 true JP2022522011A5 (enExample) 2023-03-07
JP7710374B2 JP7710374B2 (ja) 2025-07-18

Family

ID=72238666

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021550227A Active JP7710374B2 (ja) 2019-02-28 2020-02-28 骨肉腫を治療するための組成物及び使用方法

Country Status (7)

Country Link
US (1) US20220162298A1 (enExample)
EP (1) EP3931222A4 (enExample)
JP (1) JP7710374B2 (enExample)
CN (2) CN113574070B (enExample)
AU (1) AU2020229374A1 (enExample)
CA (1) CA3131925A1 (enExample)
WO (1) WO2020176844A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4277928A4 (en) * 2021-01-13 2025-03-19 Board of Regents, The University of Texas System COMPOSITIONS AND METHODS FOR THE TREATMENT OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS AND JOINT AND TENDON DISEASES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013091903A1 (en) * 2011-12-22 2013-06-27 Novo Nordisk A/S Anti-crac channel antibodies
WO2015027120A1 (en) * 2013-08-21 2015-02-26 Jiang Jean X Compositions and methods for targeting connexin hemichannels
AU2017224122B2 (en) * 2016-02-26 2024-04-11 The Board Of Regents Of The University Of Texas System Connexin (Cx) 43 hemichannel-binding antibodies and uses thereof
CN116854816A (zh) * 2018-04-02 2023-10-10 阿拉玛布治疗学股份有限公司 连接蛋白43抗体及其用途

Similar Documents

Publication Publication Date Title
JP2024150751A5 (enExample)
JP2025011178A5 (enExample)
JP2019505527A5 (enExample)
JP2023548443A5 (enExample)
JP2021511387A5 (enExample)
JP2021524256A5 (enExample)
JP2021510736A5 (enExample)
RU2018129874A (ru) Антитела против фактора свертывания xi
JP2019527194A5 (enExample)
JP2017536354A5 (enExample)
RU2014105496A (ru) Способы снижения числа эозинофилов
JP2025516381A5 (enExample)
JP2024532489A5 (enExample)
JP2021515793A5 (enExample)
JP2011516041A5 (enExample)
JP2022545741A5 (enExample)
JPWO2020059847A5 (enExample)
JP2021520393A5 (enExample)
JP2024016024A5 (enExample)
JP2022553851A5 (enExample)
RU2018107693A (ru) Комбинированные виды лечения и их варианты применения и способы
JP2021531255A5 (enExample)
JP2018529661A5 (enExample)
JP2024503784A5 (enExample)
JP2023076596A5 (enExample)